SRINAGAR: The National Pharmaceutical Pricing Authority (NPPA) has reduced the retail prices of 35 essential drugs to enhance affordability, the Ministry of Chemicals and Fertilizers announced on Sunday as reported by India Today.

The revised rates apply to key formulations used in treating chronic conditions, including cardiovascular, diabetic, anti-inflammatory, antibiotic, and psychiatric disorders. Affected medicines include combinations of Aceclofenac-Paracetamol-Trypsin Chymotrypsin, Amoxycillin with Potassium Clavulanate, Atorvastatin with Clopidogrel, and modern oral anti-diabetics like Empagliflozin, Sitagliptin, and Metformin.

Prices now range from Rs 13 to Rs 31.77. For instance, a heart drug combining Atorvastatin 40 mg and Clopidogrel 75 mg is priced at Rs 25.61. Pediatric formulations and supplements like Cholecalciferol drops are also covered.

Retailers must display updated price lists prominently. Violations may lead to penalties under the DPCO, 2013, and Essential Commodities Act, 1955. Prices exclude GST, and manufacturers must report updates to the NPPA and state regulators.

The NPPA oversees pricing of both controlled and decontrolled drugs in India.